The Multiple Myeloma Research Consortium (MMRC) today announced that it has expanded its clinical research network to include Baylor Charles A. Sammons Cancer Center (Dallas, TX), Sarah Cannon /Research Institute (SCRI, Nashville, TN) and Virginia Cancer Specialists (Fairfax, VA). These new centers join the 13 existing MMRC Member Institutions in promoting and facilitating collaborative research and accelerating drug development in multiple myeloma, an incurable blood cancer.
“Following a rigorous evaluation, Baylor Sammons, Sarah Cannon, and Virginia Cancer Specialists were selected, based on both their extensive experience in conducting clinical trials and their impressive reach to the patient community”
As MMRC Member Institutions, Baylor Sammons Cancer Center, SCRI, and Virginia Cancer Specialists will participate fully in all clinical research activities of the Consortium, including Phase I and II clinical trials of promising myeloma treatments. To date, the MMRC has advanced 27 early-stage clinical trials. MMRC Member Institutions also contribute to the MMRC Tissue Bank, which houses a critical mass of highly-annotated bone marrow and peripheral blood samples from multiple myeloma patients, and serves as a bridge between laboratory and clinical research.
"Following a rigorous evaluation, Baylor Sammons, Sarah Cannon, and Virginia Cancer Specialists were selected, based on both their extensive experience in conducting clinical trials and their impressive reach to the patient community", said Kathy Giusti, Founder and CEO of the MMRC. "We are excited to welcome them all, and look forward to working in partnership with our elite membership to bring patients new treatments they urgently need."
FDA approval of Anktiva heralds a new era in the treatment of BCG-unresponsive non–muscle-invasive bladder cancer